Skip to main content

Advertisement

Fig. 7 | Alzheimer's Research & Therapy

Fig. 7

From: Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays

Fig. 7

The timing of guanidine hydrochloride (GuHCl) denaturation impacts baseline cerebrospinal fluid (CSF) amyloid-β 1–42 (Aβ1–42) recovery in healthy control subjects and subjects with dementia as measured by 2D ultraperformance LC-MS/MS. a CSF collection workflows to assess the impact of earlier GuHCl denaturation on CSF Aβ recovery from Eppendorf LoBind® tubes. Condition 1: GuHCl added to CSF immediately after collection; condition 2: GuHCl denaturation immediately before subaliquoting; condition 3: GuHCl denaturation after subaliquoting and immediately before analysis; condition 4: into LoBind® tubes immediately after collection, GuHCl denaturation immediately before analysis. b1–42 concentrations recovered from the CSF of control subjects (black triangles, n = 10) and patients with dementia (red circles, n = 10) in conditions 2, 3, and 4 as a percentage of individual recoveries in condition 1. c1–40 concentrations recovered from the CSF of control subjects (black triangles) and patients with dementia (red circles) in conditions 2, 3, and 4 as a percentage of individual recoveries in condition 1. d CSF Aβ1–42/Aβ1–40 ratios from control subjects (black triangles) and patients with dementia (red circles) in conditions 2, 3, and 4 as a percentage of the ratio in condition 1. All measurements were made within 2 weeks of collection. ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, NS = not significant (p > 0.05)

Back to article page